National Institutes of Health (NIH) Awards Sedia Biosciences $195,490 SBIR Grant For Rapid HIV-1 Incidence Assay

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PORTLAND, Ore.--(BUSINESS WIRE)--Sedia Biosciences Corporation announced today that it has received a Notice of Award from the National Institutes of Health (NIH) for a Small Business Innovation Research (SBIR) Grant to develop a Rapid HIV-1 Incidence (or Recency) Assay that will determine recency of HIV-1 infection in as little as 20 minutes from less than a single drop of blood. Initially, the assay would enable epidemiologists to estimate HIV-1 incidence rates without relying on laboratory based assays or longitudinal cohort studies. However, it could ultimately provide clinicians with additional disease state data to improve patient management by identifying early infections which are at highest risk of transmission. Furthermore, treatment of such early infections provides the greatest opportunity to reduce viral levels before viral reservoirs become established. The ability to intervene prior to establishment of viral reservoirs is of particular interest to researchers working to develop a cure for HIV infections, since virus established in those reservoirs are particularly resistant to most antiretroviral therapies.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC